
Study prompts rethinking lifelong beta-blocker therapy after heart attack
A South Korean NEJM study found that among stable, low-risk heart-attack survivors, stopping beta-blockers after one year was as safe as continuing them for years: 58 events (7.2%) vs 74 (9%), deaths 2.4% vs 3.4%, recurrent heart attack 2.3% vs 2.6%, and heart-failure hospitalizations about 2% in both groups, with modest increases in BP/HR but SBP kept under 130. The results—alongside evolving guidelines—suggest lifelong beta-blockers may not be necessary for all, supporting shared decision-making and potential cost savings, though not all patients are candidates and further data are needed.













